Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized controlled trial of AAV5-hRKp.RPGR for X-linked retinitis pigmentosa due to RPGR variants
MOH_2022-03-28_009699Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Retinal function by static perimetry. Started Aug 2021; status: recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on MOH_2022-03-28_009699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-28_009699.